{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T04:03:43Z","timestamp":1774670623494,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003669","name":"Korea Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["4834-303"],"award-info":[{"award-number":["4834-303"]}],"id":[{"id":"10.13039\/501100003669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The emergence of influenza viruses resistant to anti-influenza drugs is a threat to global public health. The Korea Centers for Disease Control and Prevention operates the Korea Influenza and Respiratory Viruses Surveillance System (KINRESS) to monitor epidemics of influenza and Severe Acute Respiratory Infection (SARI) to identify mutated influenza viruses affecting drug resistance, pathogenesis, and transmission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Oropharyngeal swab samples were collected from KINRESS and SARI during the 2018\u20132019 season. The specimens confirmed influenza virus using real-time RT-PCR on inoculated MDCK cells. HA and NA sequences of the influenza viruses were analyzed for phylogeny and mutations. Neuraminidase inhibition and hemagglutination inhibition assays were utilized to characterize the isolates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two A(H1N1)pdm09 isolates harboring an H275Y substitution in the neuraminidase sequence were detected in patients with acute hematologic cancer. They had prolonged respiratory symptoms, with the virus present in the respiratory tract despite oseltamivir and peramivir treatment. Through the neuraminidase inhibition assay, both viruses were found to be resistant to oseltamivir and peramivir, but not to zanamivir. Although hemagglutinin and neuraminidase phylogenetic analyses suggested that the 2 A(H1N1)pdm09 isolates were not identical, their antigenicity was similar to that of the 2018\u201319 influenza vaccine virus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our data indicate the utility of monitoring influenza-infected immunocompromised patients in general hospitals for the early detection of emerging neuraminidase inhibitor-resistant viruses and maintaining continuous laboratory surveillance of patients with influenza-like illness in sentinel clinics to monitor the spread of such new variants. Finally, characterization of the virus can inform the risk assessment for future epidemics and pandemics caused by drug-resistant influenza viruses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12985-020-01375-1","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T09:03:52Z","timestamp":1594026232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Characterization of neuraminidase inhibitor-resistant influenza virus isolates from immunocompromised patients in the Republic of Korea"],"prefix":"10.1186","volume":"17","author":[{"given":"Heui Man","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namjoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi-Seon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-5533","authenticated-orcid":false,"given":"Yoon-Seok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"key":"1375_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1136\/bmj.326.7401.1235","volume":"326","author":"NJ Cooper","year":"2003","unstructured":"Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza a and B: systematic review and meta-analyses of randomized controlled trials. BMJ. 2003;326:1235.","journal-title":"BMJ."},{"key":"1375_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/irv.12047","volume":"7","author":"JL McKimm-Breschkin","year":"2013","unstructured":"McKimm-Breschkin JL. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses. 2013;7:25\u201336.","journal-title":"Influenza Other Respir Viruses"},{"key":"1375_CR3","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40265-018-0899-1","volume":"78","author":"YA Heo","year":"2018","unstructured":"Heo YA. Baloxavir: first global approval. Drugs. 2018;78:693\u20137.","journal-title":"Drugs."},{"key":"1375_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.meegid.2018.10.023","volume":"67","author":"E Moasser","year":"2019","unstructured":"Moasser E, Moasser A, Zaraket H. Incidence of antiviral drug resistance markers among human influenza a viruses in the eastern Mediterranean region, 2005-2016. Infect Genet Evol. 2019;67:60\u20136.","journal-title":"Infect Genet Evol"},{"key":"1375_CR5","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s10096-011-1482-9","volume":"31","author":"M Redlberger-Fritz","year":"2012","unstructured":"Redlberger-Fritz M, Aberle SW, Strassi R, Popow-Kraupp T. Rapid identification of neuraminidase inhibitor resistance mutations in seasonal influenza virus a (H1N1), a (H1N1) 2009, and a (H3N2) subtypes by melting point analysis. Eur J Clin Microbiol Infect Dis. 2012;31:1593\u2013601.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1375_CR6","volume-title":"Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitors (NAI)","author":"World Health Organization","year":"2018","unstructured":"World Health Organization. Summary table of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). In: Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: Neuraminidase inhibitors (NAI); 2018. https:\/\/www.who.int\/influenza\/gisrs_laboratory\/antiviral_susceptibility\/nai_overview\/en\/. Accessed 26 Apr 2018."},{"key":"1375_CR7","unstructured":"A*STAR Bioinformatics Institute. FluSurver. http:\/\/flusurver.bii.a-star.edu.sg\/ Accessed 14 Mar 2016."},{"key":"1375_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3851\/IMP2067","volume":"17","author":"HT Nguyen","year":"2012","unstructured":"Nguyen HT, Fry AM, Gubareva LV. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivi Ther. 2012;17:159\u201373.","journal-title":"Antivi Ther"},{"key":"1375_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1056\/NEJM200302273480923","volume":"348","author":"DM Weinstock","year":"2003","unstructured":"Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza a virus in an immunocompromised patient. New Engl J Med. 2003;348:867\u20138.","journal-title":"New Engl J Med"},{"key":"1375_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12275-013-2452-y","volume":"51","author":"JH Choi","year":"2013","unstructured":"Choi JH, Kim MS, Lee JY, Lee NJ, Kwon D, Kang MG, et al. Development and evaluation of multiplex real-time RT-PCR assays for seasonal, pandemic a\/H1pdm09 and avian a\/H5 influenza viruses detection. J Microbiol. 2013;51:252\u20137.","journal-title":"J Microbiol"},{"key":"1375_CR11","doi-asserted-by":"publisher","first-page":"8488","DOI":"10.1038\/s41598-017-08282-6","volume":"7","author":"SS Liu","year":"2017","unstructured":"Liu SS, Jiao XY, Wang S, Su WZ, Jiang LZ, Zhang X, et al. Susceptibility of influenza a (H1N1)\/pdm2009, seasonal a (H3N2) and B viruses to Oseltamivir in Guangdong, China between 2009 and 2014. Sci Rep. 2017;7:8488.","journal-title":"Sci Rep"},{"key":"1375_CR12","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s007050170002","volume":"146","author":"E Hoffmann","year":"2001","unstructured":"Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR. Universal primer set for the full-length amplification of all influenza a viruses. Arch Virol. 2001;146:2275\u201389.","journal-title":"Arch Virol"},{"key":"1375_CR13","volume-title":"Influenza virus characterization, Summary Europe, May 2019","author":"European Centre for Disease Prevention and Control","year":"2019","unstructured":"European Centre for Disease Prevention and Control. Influenza virus characterization, Summary Europe, May 2019. 2019. https:\/\/www.ecdc.europa.eu\/en\/seasonal-influenza\/surveillance-and-disease-data\/influenza-virus-characterisation. Accessed 10 June 2019."},{"key":"1375_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.antiviral.2018.07.001","volume":"157","author":"A Lackenby","year":"2018","unstructured":"Lackenby A, Besselaar TG, Daniels RS, Fry A, Gregory V, Gubareva LV, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors and status of novel antivirals, 2016-2017. Antivir Res. 2018;157:38\u201346.","journal-title":"Antivir Res"},{"key":"1375_CR15","unstructured":"WHO GISRS Antiviral Susceptibility Expert Working Group. Summary of neuraminidase amino acid substitutions associated with reduced inhibition by neuraminidase inhibitors (NAI). Last updated 21 October 2016: World Health Organization; 2016."},{"key":"1375_CR16","volume-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza. 2011. ISBN 9789241518090."},{"key":"1375_CR17","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.3390\/v2102269","volume":"2","author":"M Okomo-Adhiambo","year":"2010","unstructured":"Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, et al. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses. 2010;2:2269\u201389.","journal-title":"Viruses."},{"key":"1375_CR18","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/cid\/cit725","volume":"58","author":"MJ Memoli","year":"2013","unstructured":"Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, et al. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2013;58:214\u201324.","journal-title":"Clin Infect Dis"},{"key":"1375_CR19","doi-asserted-by":"publisher","first-page":"30445","DOI":"10.2807\/1560-7917.ES.2017.22.3.30445","volume":"22","author":"R Trebbien","year":"2017","unstructured":"Trebbien R, Pedersen SS, Vorborg K, Franck KT, Fischer TK. Development of oseltamivir and zanamivir resistance in influenza a (H1N1) pdm09 virus, Denmark, 2014. Euro Surveill. 2017;22:30445.","journal-title":"Euro Surveill"},{"key":"1375_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003343","volume":"9","author":"E van der Vries","year":"2013","unstructured":"van der Vries E, Stittelaar KJ, van Amerongen G, Veldhuis Kroeze EJ, de Waal L, Fraaij PL, et al. Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets. PLoS Pathog. 2013;9:e1003343.","journal-title":"PLoS Pathog"},{"key":"1375_CR21","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1128\/JVI.02690-13","volume":"88","author":"RP de Vries","year":"2014","unstructured":"de Vries RP, Zhu X, McBride R, Rigter A, Hanson A, Zhong G, et al. Hemagglutinin receptor specificity and structural analyses of respiratory droplet-transmissible H5N1 viruses. J Virol. 2014;88:768\u201373.","journal-title":"J Virol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01375-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01375-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T20:13:24Z","timestamp":1625516004000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01375-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1375"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01375-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-18137\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"18 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experimental procedures were approved by the institutional review boards of Korea Centers for Disease Control and Prevention (Ethics number: 2016-05-02-P-A).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"94"}}